A Phase I/IIa multicenter study evaluating the safety and efficacy of CAR20(NAP)-T in patients with relapsed/refractory B cell lymphoma (CARMA-01)

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511844-18-00

Acronym

ELC301-CARMA-01

Enrollment

Registered

2024-09-02

Start date

2024-05-02

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mantle cell lymphoma or indolent lymphoma, Relapsed or refractory CD20+ diffuse large B-cell lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026